{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:48:34Z","timestamp":1789213714942,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370151"],"award-info":[{"award-number":["82370151"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06826-3","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:44:30Z","timestamp":1768873470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study"],"prefix":"10.1007","volume":"105","author":[{"given":"Yunfei","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingnong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"12","key":"6826_CR1","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1007\/s00277-024-06067-2","volume":"103","author":"RMH Lim","year":"2024","unstructured":"Lim RMH, Tan JY, Tan YH, Heng ZEQ, Ng LCK, Lim F et al (2024) Real-world outcomes of diffuse large B-cell lymphoma treated with frontline R-CHOP(-like) regimens in an Asian multi-ethnic population. Ann Hematol 103(12):5483\u20135493. https:\/\/doi.org\/10.1007\/s00277-024-06067-2","journal-title":"Ann Hematol"},{"issue":"4","key":"6826_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17474086.2017.1305264","volume":"10","author":"A Chiappella","year":"2017","unstructured":"Chiappella A, Castellino A, Nicolosi M, Santambrogio E, Vitolo U (2017) Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives. Expert Rev Hematol 10(4):289\u2013297. https:\/\/doi.org\/10.1080\/17474086.2017.1305264","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"6826_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A et al (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837\u2013842. https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"key":"6826_CR4","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","volume":"95","author":"K Laribi","year":"2016","unstructured":"Laribi K, Denizon N, Bolle D, Truong C, Besan\u00e7on A, Sandrini J et al (2016) R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol 95:1705\u20131714","journal-title":"Ann Hematol"},{"issue":"8","key":"6826_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922\u2013926. https:\/\/doi.org\/10.1038\/nm.3884","journal-title":"Nat Med"},{"issue":"17","key":"6826_CR6","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1158\/1078-0432.CCR-24-0183","volume":"30","author":"B Rey-Bua","year":"2024","unstructured":"Rey-Bua B, Grande C, Sanchez Blanco JJ, Abrisqueta P, Gutierrez A, Ramirez Payer A et al (2024) Ibrutinib in combination with R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of nongerminal center B-cell-like type: phase II clinical trial of the Spanish GELTAMO group. Clin Cancer Res 30(17):3704\u20133714. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0183","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6826_CR7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1182\/bloodadvances.2020003698","volume":"6","author":"H Yang","year":"2022","unstructured":"Yang H, Xiang B, Song Y, Zhang H, Zhao W, Zou D et al (2022) Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. Blood Adv 6(6):1629\u20131636. https:\/\/doi.org\/10.1182\/bloodadvances.2020003698","journal-title":"Blood Adv"},{"issue":"8","key":"6826_CR8","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1007\/s10238-023-01231-w","volume":"23","author":"R Wei","year":"2023","unstructured":"Wei R, Wu Y, Jiang S, Zhang A, Zhang L, Liu L et al (2023) Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis. Clin Exp Med 23(8):4609\u20134621. https:\/\/doi.org\/10.1007\/s10238-023-01231-w","journal-title":"Clin Exp Med"},{"issue":"1","key":"6826_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40164-022-00314-w","volume":"11","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhang X, Wei J, Yang C, Tong H, Mai W et al (2022) Rituximab, Lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center. Experimental Hematol Oncol 11(1):57","journal-title":"Experimental Hematol Oncol"},{"issue":"12","key":"6826_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.20.01375","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM et al (2021) Addition of Lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-Cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol 39(12):1329\u20131338. https:\/\/doi.org\/10.1200\/JCO.20.01375","journal-title":"J Clin Oncol"},{"issue":"7","key":"6826_CR11","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2666-7568(22)00123-4","volume":"3","author":"PP Xu","year":"2022","unstructured":"Xu PP, Shi ZY, Qian Y, Cheng S, Zhu Y, Jiang L et al (2022) Ibrutinib, rituximab, and Lenalidomide in unfit or frail patients aged 75 years or older with de Novo diffuse large B-cell lymphoma: a phase 2, single-arm study. Lancet Healthy Longev 3(7):e481\u2013e490. https:\/\/doi.org\/10.1016\/S2666-7568(22)00123-4","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"6826_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.22.00597","volume":"41","author":"J Westin","year":"2023","unstructured":"Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ et al (2023) Smart start: Rituximab, Lenalidomide, and ibrutinib in patients with newly diagnosed large B-Cell lymphoma. J Clin Oncol 41(4):745\u2013755. https:\/\/doi.org\/10.1200\/JCO.22.00597","journal-title":"J Clin Oncol"},{"issue":"16","key":"6826_CR13","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","volume":"141","author":"Y Song","year":"2023","unstructured":"Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H et al (2023) Polatuzumab Vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood 141(16):1971\u20131981. https:\/\/doi.org\/10.1182\/blood.2022017734","journal-title":"Blood"},{"issue":"5","key":"6826_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F et al (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical hodgkin lymphoma: preliminary results of a single-centre phase II study. Br J Haematol 198(5):847\u2013860. https:\/\/doi.org\/10.1111\/bjh.18348","journal-title":"Br J Haematol"},{"issue":"11","key":"6826_CR15","first-page":"1296","volume":"88","author":"M Picardi","year":"2003","unstructured":"Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B et al (2003) Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin\u2019s lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 88(11):1296\u20131303","journal-title":"Haematologica"},{"issue":"5","key":"6826_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/blood-2018-10-878892","volume":"133","author":"M Picardi","year":"2019","unstructured":"Picardi M, Della Pepa R, Giordano C, Zacheo I, Pugliese N, Mortaruolo C et al (2019) Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. Blood 133(5):498\u2013501. https:\/\/doi.org\/10.1182\/blood-2018-10-878892","journal-title":"Blood"},{"key":"6826_CR17","doi-asserted-by":"publisher","first-page":"1130899","DOI":"10.3389\/fonc.2023.1130899","volume":"13","author":"C Giordano","year":"2023","unstructured":"Giordano C, Picardi M, Pugliese N, Vincenzi A, Abagnale DP, De Fazio L et al (2023) Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21. Front Oncol 13:1130899. https:\/\/doi.org\/10.3389\/fonc.2023.1130899","journal-title":"Front Oncol"},{"issue":"1","key":"6826_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1148\/radiol.14132154","volume":"272","author":"M Picardi","year":"2014","unstructured":"Picardi M, Pugliese N, Cirillo M, Zeppa P, Cozzolino I, Ciancia G et al (2014) Advanced-stage hodgkin lymphoma: US\/chest radiography for detection of relapse in patients in first complete remission\u2013a randomized trial of routine surveillance imaging procedures. Radiology 272(1):262\u2013274. https:\/\/doi.org\/10.1148\/radiol.14132154","journal-title":"Radiology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06826-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:32:59Z","timestamp":1770262379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06826-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6826"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06826-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee and Institutional Review Board of the First Affiliated Hospital, Zhejiang University School of Medicine (No. IIT20250827B-R1) approved this study. All investigations were conducted in accordance with the Declaration of Helsinki. Informed consent from patients was waived by the ethics committee based on this study being retrospective in nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}